GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
9 July 2013 | By GlaxoSmithKline
GSK announced submission of NDAs to the US FDA for use of dabrafenib...
List view / Grid view
9 July 2013 | By GlaxoSmithKline
GSK announced submission of NDAs to the US FDA for use of dabrafenib...
9 July 2013 | By AstraZeneca
AstraZeneca enters agreement with University of Cambridge & Cancer Research UK...
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
8 July 2013 | By Just:: Health PR
Sanofi is delighted to announce the winners of its 2013 Patient Group Bursary scheme...
8 July 2013 | By Boehringer Ingelheim
EMA accepted companies' MAA...
8 July 2013 | By Novartis
All primary & secondary endpoints were met...
8 July 2013 | By Novartis
Novartis has entered into a development and licensing agreement with Biological E Limited...
4 July 2013 | By GlaxoSmithKline
A student has become the first to graduate from a landmark research programme run by the University of Strathclyde...
3 July 2013 | By Roche
FDA decision on the GA101 BLA is expected by the end of 2013...
2 July 2013 | By Nova Laboratories Ltd
The European Medicines Agency has approved an extension of the in-use shelf life for Xaluprine...
2 July 2013 | By Biogen Idec
Biogen Idec and Sobi presented new findings...
2 July 2013 | By Roche
The U.S. FDA has accepted the company’s sBLA for the use of a Perjeta®...
2 July 2013 | By Roche
Strengthening Roche's commitment to hematology testing...
1 July 2013 | By Merck
“We will evaluate the requests outlined in the Complete Response Letter..."
1 July 2013 | By Merck
New U.S. labeling for ISENTRESS® (raltegravir) to include 240-week results from STARTMRK study...